Medivir AB announced promising interim safety and efficacy data from its ongoing phase 1b/2a study of first-in-class candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.
